Inhaled Tobramycin for Treatment of Ventilator-Associated Pneumonia: The Interplay of Patient, Drug, and Device

References

1. 1.↵
   1. Feeley TW,
   2. Du Moulin GC,
   3. Hedley-Whyte J,
   4. Bushnell LS,
   5. Gilbert JP,
   6. Feingold DS

   . Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975;293(10):471-475.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Wong FJ,
   2. Dudney T,
   3. Dhand R

   . Aerosolized antibiotics for treatment of pneumonia in mechanically ventilated subjects. Respir Care 2019;64(8):962-979.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Solé-Lleonart C,
   2. Rouby J-J,
   3. Blot S,
   4. Poulakou G,
   5. Chastre J,
   6. Palmer LB,
   7. et al

   . Nebulization of anti-infective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology 2017;126(5):890-908.

   OpenUrl
4. 4.↵
   1. Palmer LB

   . Ventilator-associated infection: the role for inhaled antibiotics. Curr Opin Pulm Med 2015;21(3):239-242.

   OpenUrl
5. 5.↵
   1. Palmer LB

   . Inhaled antibiotics for ventilator-associated infections. Infect Dis Clin North Am 2017;31(3):577-591.

   OpenUrl
6. 6.↵
   1. Dhand R

   . The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2018;31(3):121-138.

   OpenUrl
7. 7.↵
   1. Luyt C-E,
   2. Hékimian G,
   3. Bréchot N,
   4. Chastre J

   . Aerosol therapy for pneumonia in the intensive care unit. Clin Chest Med 2018;39(4):823-836.

   OpenUrl
8. 8.↵
   1. Palmer LB

   . Aerosolized antibiotics in the intensive care unit. Clin Chest Med 2011;32(3):559-574.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Niederman MS,
   2. Alder J,
   3. Bassetti M,
   4. Boateng F,
   5. Cao B,
   6. Corkery K,
   7. et al

   . Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomized, placebo-controlled, phase 3 superiority trial. Lancet Infect Dis 2020;20(3):330-340.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Kollef MH,
    2. Ricard JD,
    3. Roux D,
    4. Francois B,
    5. Ischaki E,
    6. Rozgonyi Z,
    7. et al

    . A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia. IASIS Trial. Chest 2017;151(6):1239-1246.

    OpenUrl
11. 11.↵
    1. Kalil AC,
    2. Metersky ML,
    3. Klompas M,
    4. Muscedere J,
    5. Sweeney DA,
    6. Palmer LB,
    7. et al

    . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):e61-e111.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Droege CA,
    2. Ernst NE,
    3. Foertsch MJ,
    4. Bradshaw PG,
    5. Globke AE,
    6. Gomaa D,
    7. et al

    . Assessment of detectable serum tobramycin concentrations in patients receiving inhaled tobramycin for ventilator-associated pneumonia. Respir Care 2021;67(1):16-23.
13. 13.↵
    1. de Velde F,
    2. Emonts M,
    3. Verbruggen S,
    4. van der Sijs H

    . High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure. J Antimicrob Chemother 2014;69(11):3163-3164.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Gauthier T,
    2. Wasko J,
    3. Unger N,
    4. Abbo L,
    5. Fernandez M,
    6. Aragon L,
    7. et al

    . Cost reduction of inhaled tobramycin by use of preservative-free intravenous tobramycin given via inhalation. Antibiotics (Basel) 2015;5(1):2.

    OpenUrl
15. 15.↵
    1. Alothman GA,
    2. Alsaadi MM,
    3. Ho BL,
    4. Ho SL,
    5. Dupuis A,
    6. Corey M,
    7. Coates AL

    . Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122(3):930-934.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Drobnic ME,
    2. Suñé P,
    3. Montoro JB,
    4. Ferrer A,
    5. Orriols R

    . Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Dhand R

    . The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007;52(7):866-884.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Rello J,
    2. Solé-Lleonart C,
    3. Rouby JJ,
    4. Chastre J,
    5. Blot S,
    6. Poulakou G,
    7. et al

    . Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2017;23(9):629-639.

    OpenUrl
19. 19.↵
    1. Rello J,
    2. Rouby JJ,
    3. Solé-Lleonart C,
    4. Chastre J,
    5. Blot S,
    6. Luyt CE,
    7. et al

    . Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect 2017;23(9):640-646.

    OpenUrl
20. 20.↵
    1. Dhand R

    . How should aerosols be delivered during invasive mechanical ventilation? Respir Care 2017;62(10):1343-1367.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Ari A,
    2. Atalay OT,
    3. Harwood R,
    4. Sheard MM,
    5. Aljamhan EA,
    6. Fink JB

    . Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010;55(7):845-851.

    OpenUrlAbstract/FREE Full Text